Reaching hepatitis C virus elimination targets requires health system interventions to enhance the care cascade
- PMID: 28797497
- DOI: 10.1016/j.drugpo.2017.07.006
Reaching hepatitis C virus elimination targets requires health system interventions to enhance the care cascade
Abstract
Background: Modelling suggests that achieving the World Health Organization's elimination targets for hepatitis C virus (HCV) is possible by scaling up use of direct-acting antiviral (DAA) therapy. However, poor linkage to health services and retention in care presents a major barrier, in particular among people who inject drugs (PWID). We identify and assess the cost-effectiveness of additional health system interventions required to achieve HCV elimination targets in Australia, a setting where all people living with HCV have access to DAA therapy.
Methods: We used a dynamic HCV transmission and liver-disease progression mathematical model among current and former PWID, capturing testing, treatment and other features of the care cascade. Interventions tested were: availability of point-of-care RNA testing; increased testing of PWID; using biomarkers in place of liver stiffness measurement; and scaling up primary care treatment delivery.
Results: The projected treatment uptake in Australia reduced the number of people living with HCV from approximately 230,000 in 2015 to approximately 24,000 by 2030 and reduced incidence by 45%. However, the majority (74%) of remaining infections were undiagnosed and among PWID. Scaling up primary care treatment delivery and using biomarkers in place of liver stiffness measurement only reduced incidence by a further 1% but saved AU$32 million by 2030, with no change to health outcomes. Additionally replacing HCV antibody testing with point-of-care RNA testing increased healthcare cost savings to AU$62 million, increased incidence reduction to 64% and gained 11,000 quality-adjusted life years, but critically, additional screening of PWID was required to achieve HCV elimination targets.
Conclusion: Even with unlimited and unrestricted access to HCV DAA treatment, interventions to improve the HCV cascade of care and target PWID will be required to achieve elimination targets.
Keywords: Cascade of care; Community-based services; Cost-effectiveness; Elimination; Hepatitis C virus; Mathematical model; People who inject drugs.
Copyright © 2017 Elsevier B.V. All rights reserved.
Similar articles
-
Is hepatitis C virus elimination possible among people living with HIV and what will it take to achieve it?J Int AIDS Soc. 2018 Apr;21 Suppl 2(Suppl Suppl 2):e25062. doi: 10.1002/jia2.25062. J Int AIDS Soc. 2018. PMID: 29633560 Free PMC article. Review.
-
Modelling the elimination of hepatitis C as a public health threat in Iceland: A goal attainable by 2020.J Hepatol. 2018 May;68(5):932-939. doi: 10.1016/j.jhep.2017.12.013. Epub 2017 Dec 21. J Hepatol. 2018. PMID: 29274408
-
Estimating the cascade of hepatitis C testing, care and treatment among people who inject drugs in Australia.Int J Drug Policy. 2017 Sep;47:77-85. doi: 10.1016/j.drugpo.2017.05.022. Epub 2017 Jun 1. Int J Drug Policy. 2017. PMID: 28578863
-
Effectiveness and cost-effectiveness of interventions targeting harm reduction and chronic hepatitis C cascade of care in people who inject drugs: The case of France.J Viral Hepat. 2018 Oct;25(10):1197-1207. doi: 10.1111/jvh.12919. Epub 2018 May 9. J Viral Hepat. 2018. PMID: 29660211
-
Is global elimination of HCV realistic?Liver Int. 2018 Feb;38 Suppl 1:40-46. doi: 10.1111/liv.13668. Liver Int. 2018. PMID: 29427499 Review.
Cited by
-
The hepatitis C virus care cascade in the New York City jail system during the direct acting antiviral treatment era, 2014-2017.EClinicalMedicine. 2020 Oct 5;27:100567. doi: 10.1016/j.eclinm.2020.100567. eCollection 2020 Oct. EClinicalMedicine. 2020. PMID: 33150329 Free PMC article.
-
Community-based provision of direct-acting antiviral therapy for hepatitis C: study protocol and challenges of a randomized controlled trial.Trials. 2018 Jul 16;19(1):383. doi: 10.1186/s13063-018-2768-3. Trials. 2018. PMID: 30012192 Free PMC article.
-
Four Weeks Treatment with Glecaprevir/Pibrentasvir + Ribavirin-A Randomized Controlled Clinical Trial.Viruses. 2022 Mar 16;14(3):614. doi: 10.3390/v14030614. Viruses. 2022. PMID: 35337021 Free PMC article. Clinical Trial.
-
Healthcare value of implementing hepatitis C screening in the adult general population in Spain.PLoS One. 2018 Nov 28;13(11):e0208036. doi: 10.1371/journal.pone.0208036. eCollection 2018. PLoS One. 2018. PMID: 30485377 Free PMC article.
-
Is hepatitis C virus elimination possible among people living with HIV and what will it take to achieve it?J Int AIDS Soc. 2018 Apr;21 Suppl 2(Suppl Suppl 2):e25062. doi: 10.1002/jia2.25062. J Int AIDS Soc. 2018. PMID: 29633560 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical